Cancer drugmaker Seattle Genetics reported stronger-than-expected revenues for the second quarter as its stock rose more than 8 percent in after-hours trading. The Bothell, Wash.-based drugmaker posted $218 million in… Read More
Seattle Genetics’ star cancer drug Adcetris has won Food and Drug Administration approval for treatment of a fast-growing type of non-Hodgkin lymphoma. The approval comes after the drug showed better… Read More